TRS 021
Alternative Names: TRS-021Latest Information Update: 07 Jul 2025
At a glance
- Originator Zhejiang Teruisi Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Jul 2025 Preclinical trials in Solid tumours in China (unspecified route) before July 2025 (Zhejiang Teruisi Biopharmaceutical pipeline, July 2025)